D
Dynavax Technologies Corp D
D
DVAX
12.870
USD
0.17
(1.30%)
مغلق
حجم التداول
65,835
الربح لكل سهم
0
العائد الربحي
-
P/E
64
حجم السوق
1,596,791,569
الأخبار المقالات
العنوان: Dynavax Technologies Corp
القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.